Evidence map›Paper›PMID 34973110›Full record

ArticleArchives of toxicology2022

Pharmacological inhibition of MERTK induces in vivo retinal degeneration: a multimodal imaging ocular safety assessment.

Gregory Hamm, Gareth Maglennon, Beth Williamson, Ruth Macdonald, Ann Doherty, Stewart Jones, Jayne Harris, James Blades, Alexander R Harmer, Peter Barton and 8 more

Open access · hybridAbstract read
In one paragraph

Article in Archives of toxicology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Progress in retinal toxicity research.Archives of toxicology · 2022
    Article
  10. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 4 countries.

Gregory Hamm *Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK.
Gareth Maglennon *Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK.
Beth WilliamsonOncology R&D, AstraZeneca, Cambridge, UK.
Ruth MacdonaldClinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK.
Ann DohertyClinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK.
Stewart JonesClinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK.
Jayne HarrisClinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK.
James BladesClinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK.
Alexander R HarmerClinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK.
Peter BartonOncology R&D, AstraZeneca, Cambridge, UK.
Philip B RawlinsDiscovery Sciences, R&D, AstraZeneca, Cambridge, UK.
Paul SmithOncology R&D, AstraZeneca, Cambridge, UK.
Jon Winter-HoltOncology R&D, AstraZeneca, Cambridge, UK.
Lindsay McMurrayOncology R&D, AstraZeneca, Cambridge, UK.
Julia JohanssonClinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Paul FitzpatrickClinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
William McCoullOncology R&D, AstraZeneca, Cambridge, UK.
Muireann CoenClinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK. muireann.coen@astrazeneca.com.ORCID 0000-0003-3542-8325
AstraZeneca (United Kingdom) · GBAstraZeneca (Sweden) · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The receptor tyrosine kinase, MERTK, plays an essential role in homeostasis of the retina via efferocytosis of shed outer nuclear segments of photoreceptors. The Royal College of Surgeons rat model of retinal degeneration has been linked to loss-of-function of MERTK, and together with the MERTK knock-out mouse, phenocopy retinitis pigmentosa in humans with MERTK mutations. Given recent efforts and interest in MERTK as a potential immuno-oncology target, development of a strategy to assess ocular safety at an early pre-clinical stage is critical. We have applied a state-of-the-art, multi-modal imaging platform to assess the in vivo effects of pharmacological inhibition of MERTK in mice. This involved the application of mass spectrometry imaging (MSI) to characterize the ocular spatial distribution of our highly selective MERTK inhibitor; AZ14145845, together with histopathology and transmission electron microscopy to characterize pathological and ultra-structural change in response to MERTK inhibition. In addition, we assessed the utility of a human retinal in vitro cell model to identify perturbation of phagocytosis post MERTK inhibition. We identified high localized total compound concentrations in the retinal pigment epithelium (RPE) and retinal lesions following 28 days of treatment with AZ14145845. These lesions were present in 4 of 8 treated animals, and were characterized by a thinning of the outer nuclear layer, loss of photoreceptors (PR) and accumulation of photoreceptor outer segments at the interface of the RPE and PRs. Furthermore, the lesions were very similar to that shown in the RCS rat and MERTK knock-out mouse, suggesting a MERTK-induced mechanism of PR cell death. This was further supported by the observation of reduced phagocytosis in the human retinal cell model following treatment with AZ14145845. Our study provides a viable, translational strategy to investigate the pre-clinical toxicity of MERTK inhibitors but is equally transferrable to novel chemotypes.

Indexed as

AnimalsCell Linec-Mer Tyrosine KinaseFemaleHumansMaleMass SpectrometryMiceMice, Inbred C57BLMice, KnockoutMultimodal ImagingPhagocytosisPhotoreceptor Cells, VertebrateRatsRats, Long-EvansRats, Wistarc-Mer Tyrosine KinaseMERTK protein, humanMertk protein, mouseMertk protein, ratMass spectrometry imagingMERTKOcular electron microscopyOcular histopathologyRetinal degenerationTAM kinases

Identifiers

PMID34973110
PMCPMC8837544
OpenAlexW4206649417

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.